These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9741368)

  • 1. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.
    Seersholm N; Kok-Jensen A
    Thorax; 1998 Apr; 53(4):265-8. PubMed ID: 9741368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?
    Seersholm N; Kok-Jensen A
    Respir Med; 1998 Feb; 92(2):241-5. PubMed ID: 9616519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).
    Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
    Thorax; 2008 Dec; 63(12):1091-5. PubMed ID: 18682522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
    Stockley RA; Edgar RG; Pillai A; Turner AM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in FEV
    Hiller AM; Piitulainen E; Jehpsson L; Tanash H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
    [No Abstract]   [Full Text] [Related]  

  • 6. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
    Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
    Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survival of patients with severe alpha 1-antitrypsin deficiency].
    Seersholm NJ; Kok-Jensen A; Dirksen A
    Ugeskr Laeger; 1995 Apr; 157(17):2432-5. PubMed ID: 7762099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
    Sclar DA; Evans MA; Robison LM; Skaer TL
    Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.
    Seersholm N; Kok-Jensen A; Dirksen A
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1922-5. PubMed ID: 8520756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases.
    Seersholm N; Kok-Jensen A; Dirksen A
    Thorax; 1994 Jul; 49(7):695-8. PubMed ID: 8066566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).
    Piitulainen E; Sveger T
    Thorax; 2002 Aug; 57(8):705-8. PubMed ID: 12149531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
    Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
    COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
    Piitulainen E; Tanash HA
    COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.
    Evald T; Dirksen A; Keittelmann S; Viskum K; Kok-Jensen A
    Lung; 1990; 168 Suppl():579-85. PubMed ID: 2117166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
    Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in severe alpha-1-antitrypsin deficiency (PiZZ).
    Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
    Respir Res; 2010 Apr; 11(1):44. PubMed ID: 20420704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
    Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
    Piitulainen E; Eriksson S
    Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.
    Bernspång E; Sveger T; Piitulainen E
    Respir Med; 2007 Sep; 101(9):1971-6. PubMed ID: 17532199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
    Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
    Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.